Payment overview · 2025
General Payments
$65,829.56
247 reported records · 19 companies
Healthcare provider profile · identity verified
Ignacio H Valdes, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · HOUSTON, TX · NPI 1760546360
Verified facts
What the public records show
CMS Open Payments records show Ignacio H Valdes, M.D. received $65,829.56 in general payments during 2025 across 247 reported records.
Neurocrine BioSciences, Inc. accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Aristada, Auvelity, Fanapt, Ingrezza, Invega Sustenna, Lybalvi, Rexulti, Secuado, Trintellix.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Lybalvi by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Auvelity by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Invega Trinza by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ingrezza by this doctor in 2024.
Noven Therapeutics, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Secuado as an associated drug or biological on 1988 records involving 1044 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Secuado by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Austedo by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25,609.01 | 38.9% | 49 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21,858.79 | 33.2% | 56 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16,274.82 | 24.7% | 40 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $417.42 | 0.6% | 24 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $411.28 | 0.6% | 20 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $320.57 | 0.5% | 15 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $295.27 | 0.5% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $158.83 | 0.2% | 8 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $100.40 | 0.1% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $67.53 | 0.1% | 4 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $52.85 | 0.1% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $47.77 | 0.1% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $47.36 | 0.1% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $43.08 | 0.1% | 2 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $36.17 | 0.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $28.45 | 0.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.99 | 0.0% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $19.13 | 0.0% | 1 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $18.84 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $51,765.75 | 20 |
| Consulting Fee | $7,837.50 | 1 |
| Food and Beverage | $4,936.92 | 214 |
| Travel and Lodging | $1,289.39 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25,609.01 | 49 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $21,551.31 | 38 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $16,010.46 | 25 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $15,968.21 | 23 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $423.19 | 23 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $417.42 | 24 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $411.28 | 20 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $411.28 | 20 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $320.57 | 15 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $307.48 | 18 | 2025 |
Source payment records
|
|||||
| INVEGA Normalized: invega |
Drug | Janssen Pharmaceuticals, Inc | $149.89 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $145.38 | 10 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $100.40 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $67.53 | 4 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $52.85 | 3 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $47.77 | 2 | 2025 |
Source payment records
|
|||||
| Onyda XR Normalized: onyda xr |
Drug | Tris Pharma Inc | $47.36 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $28.45 | 1 | 2025 |
Source payment records
|
|||||
| Secuado Normalized: secuado |
Drug | Noven Therapeutics, LLC | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 66 | exact normalized | Medicare Part D |
| ARISTADA aristada |
2025 | Aristada | 2024 | 33 | exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 71 | exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 285 | exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 74 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 97 | exact normalized | Medicare Part D |
| Secuado secuado |
2025 | Secuado | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
285 | 57 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA TRINZA open payments reported associated product |
CMS Open Payments — General Payments 8191 supporting records · 2146 recipient NPIs · example record 1174223262 |
Invega Trinza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
97 | 26 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| Noven Therapeutics, LLC Exact reporting entity; no affiliate inference |
2025 | Secuado open payments reported associated product |
CMS Open Payments — General Payments 1988 supporting records · 1044 recipient NPIs · example record 1240398301 |
Secuado · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
97 | 26 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 740 | 143 |
| Benztropine Mesylate | Benztropine Mesylate | 518 | 117 |
| Mirtazapine | Mirtazapine | 511 | 129 |
| Trazodone Hcl | Trazodone Hcl | 511 | 132 |
| Buspirone Hcl | Buspirone Hcl | 391 | 89 |
| Divalproex Sodium Er | Divalproex Sodium | 349 | 81 |
| Risperidone | Risperidone | 342 | 76 |
| Sertraline Hcl | Sertraline Hcl | 342 | 87 |
| Clonazepam | Clonazepam | 312 | 64 |
| Invega Sustenna | Paliperidone Palmitate | 285 | 57 |
| Gabapentin | Gabapentin | 254 | 74 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 248 | 74 |
| Lithium Carbonate | Lithium Carbonate | 244 | 60 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 216 | 63 |
| Aripiprazole | Aripiprazole | 209 | 61 |
| Fluoxetine Hcl | Fluoxetine Hcl | 184 | 37 |
| Olanzapine | Olanzapine | 180 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 39 |
| Bupropion Xl | Bupropion Hcl | 158 | 34 |
| Divalproex Sodium | Divalproex Sodium | 155 | 35 |
| Prazosin Hcl | Prazosin Hcl | 149 | 31 |
| Lurasidone Hcl | Lurasidone Hcl | 136 | 31 |
| Propranolol Hcl | Propranolol Hcl | 123 | 25 |
| Haloperidol | Haloperidol | 116 | 31 |
| Lithium Carbonate Er | Lithium Carbonate | 107 | 23 |
| Oxcarbazepine | Oxcarbazepine | 102 | 20 |
| Adderall Xr | Dextroamphetamine/Amphetamine | 100 | 34 |
| Rexulti | Brexpiprazole | 97 | 26 |
| Haloperidol Decanoate | Haloperidol Decanoate | 91 | 24 |
| Varenicline Tartrate | Varenicline Tartrate | 87 | 18 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 79 | 15 |
| Lorazepam | Lorazepam | 78 | 18 |
| Lybalvi | Olanzapine/Samidorphan Malate | 74 | 22 |
| Clonidine Hcl | Clonidine Hcl | 72 | 13 |
| Ingrezza | Valbenazine Tosylate | 71 | 14 |
| Atomoxetine Hcl | Atomoxetine Hcl | 67 | 24 |
| Abilify Maintena | Aripiprazole | 66 | 16 |
| Lamotrigine | Lamotrigine | 61 | 15 |
| Paliperidone Er | Paliperidone | 60 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 59 | 14 |
| Topiramate | Topiramate | 58 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 12 |
| Diazepam | Diazepam | 56 | 15 |
| Amantadine | Amantadine Hcl | 55 | 16 |
| Desmopressin Acetate | Desmopressin Acetate | 53 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 11 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 47 | 16 |
| Carbamazepine | Carbamazepine | 46 | 11 |
| Memantine Hcl | Memantine Hcl | 44 | 12 |
| Austedo | Deutetrabenazine | 42 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 41 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 38 | 13 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 34 | suppressed |
| Aristada | Aripiprazole Lauroxil | 33 | 14 |
| Guanfacine Hcl Er | Guanfacine Hcl | 33 | suppressed |
| Metformin Hcl | Metformin Hcl | 33 | 13 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 30 | suppressed |
| Clozapine | Clozapine | 29 | suppressed |
| Perseris | Risperidone | 29 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 27 | 13 |
| Fluphenazine Hcl | Fluphenazine Hcl | 26 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Fanapt | Iloperidone | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Secuado | Asenapine | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $65,829.56 · 247 records | Neurocrine BioSciences, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, INVEGA, INVEGA SUSTENNA, Jornay PM, LOREEV XR, LYBALVI, Onyda XR, Qelbree, REXULTI, SUBLOCADE, Secuado, TRINTELLIX, UZEDY, Xelstrym | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error